10 news items
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
REGN
16 Jun 24
. Together, they provide us with unique combinatorial flexibility to develop customized and potentially synergistic cancer treatments. Our research
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN
11 Jun 24
that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN
31 May 24
conditions, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN
31 May 24
on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
REGN
31 May 24
crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well
k55o1k4cm6syod8xzoyve6t
REGN
31 May 24
of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers
d4fqq5tce4dbn
REGN
20 May 24
of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers
8bo7k
REGN
20 May 24
crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our
yxm 80o3m5kc4uzc4f
REGN
13 May 24
on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees
7bxgris8r94fdv8qh iy
REGN
7 Apr 24
therapeutic modalities. Together, they provide us with unique combinatorial flexibility to develop customized and potentially synergistic cancer treatments
- Prev
- 1
- Next